Craig Parker, Surrozen CEO
In add-on to eye disease pipeline, Boehringer pays Surrozen to acquire rights to Wnt drug
Boehringer Ingelheim wants in on Wnt, and it’s willing to cash out the big bucks if it pans out.
The deal was announced by San …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
